NEW YORK, NY / ACCESSWIRE / January 28, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

ADMS Shareholders Click Here: https://www.zlk.com/pslra-1/adamas-pharmaceuticals-inc-loss-form?prid=5368&wire=1
GDOT Shareholders Click Here: https://www.zlk.com/pslra-1/green-dot-corporation-loss-form?prid=5368&wire=1
QD Shareholders Click Here: https://www.zlk.com/pslra-1/qudian-inc-loss-form?prid=5368&wire=1

* ADDITIONAL INFORMATION BELOW *

Adamas Pharmaceuticals, Inc. (NASDAQGM:ADMS)

ADMS Lawsuit on behalf of: investors who purchased August 8, 2017 – September 30, 2019
Lead Plaintiff Deadline : February 10, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/adamas-pharmaceuticals-inc-loss-form?prid=5368&wire=1

According to the filed complaint, during the class period, Adamas Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) health insurers were excluding Adamas's primary product, GOCOVRI, from their prescription formularies or requiring patients to use "step therapy" – i.e., making patients try immediate-release amantadine prior to covering GOCOVRI; (2) the rapid increase in physicians prescribing GOCOVRI during the Class Period was not due to its efficacy; and (3) as a result of the foregoing, the Company's financial statements about Adamas's business, operations, and prospects were materially false and misleading at all relevant times.

Green Dot Corporation (NYSE:GDOT)

GDOT Lawsuit on behalf of: investors who purchased May 9, 2018 – November 7, 2019
Lead Plaintiff Deadline : February 18, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/green-dot-corporation-loss-form?prid=5368&wire=1

According to the filed complaint, during the class period, Green Dot Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) Green Dot's strategy to attract "high-value" long-term customers was at the expense of "one and done" customers; (2) Green Dot's "one and done" customers represented a significant source of revenues in its legacy segment; (3) consequently, Green Dot's strategy was self-sabotaging; and (4) as a result of the foregoing, Defendants' statements about its business and operations were materially false and misleading at all relevant times.

Qudian Inc. (NYSE:QD)

QD Lawsuit on behalf of: investors who purchased December 13, 2018 – January 15, 2020
Lead Plaintiff Deadline : March 23, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/qudian-inc-loss-form?prid=5368&wire=1

According to the filed complaint, during the class period, Qudian Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) regulatory developments in China threatened to negatively impact Qudian's fiscal full year 2019 ("FY19") financial results; (ii) Qudian's business was unprepared to mitigate the risks associated with these regulatory changes; (iii) as a result, Qudian's loan portfolio was plagued by growing delinquency rates; (iv) all of the foregoing made Qudian's repeated assertions concerning its FY19 financial guidance unrealistic; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 574359

TORONTO, ON / ACCESSWIRE / January 28, 2020 / Adcore Inc. (the "Corporation" or "Adcore") (TSXV:ADCO), a leading provider of machine-learning powered advertising technologies used by digital agencies and advertisers to enhance and maximize Search Engine Marketing ("SEM"), announced today that Donville Kent Asset Management Inc. ("Donville Kent"), a Toronto based North American equity fund, has selected Adcore as one of the twelve stocks to own in the next decade in the January 2020 edition of its ROE Reporter publication.

In the January 2020 issue, Donville Kent selected companies they think "will become the big winners in the next decade". In this report, Donville Kent stated that the sector they think will produce a disproportionate number of winners over the next decade is the Canadian software industry, a sector which Adcore is a proud member of.

Furthermore, Donville Kent added that "the big winners in the coming decades will likely come from companies with market caps of less than a billion dollars, that trade on reasonable valuations, and have relatively high margins".

Adcore's Chief Executive Officer, Omri Brill, commented on the news, "Being on this exclusive list of twelve stocks to own in the next decade is a great honor for Adcore".

Mr. Brill continued, "We are very lucky to be part of the fast-growing Canadian software sector, comprised of companies with high returns on equity and profit margins. Adcore definitely checks all the boxes in Donville Kent's requirements list for the next decade's big winners.

Adcore is starting this decade with a relatively modest market cap but is in an excellent position to rapidly grow and is just getting started on its journey as a Canadian public company."

Click here for Donville Kent's full report or by visiting https://donvillekent.com/about/

ABOUT ADCORE

Adcore is a leading provider of machine-learning powered advertising technologies. Adcore's suite of solutions empowers digital advertisers with automated solutions to enhance and maximize their Search Engine Marketing ("SEM"). Adcore's technologies are designed for in-house marketing professionals, freelancers and advertising agencies to scale their SEM activity and maximize their ROI.

By combining extensive industry knowledge and experience with its proprietary artificial intelligence ("AI") engine, Adcore offers a unique SEM platform. In addition to being named numerous times on Deloitte's Fast 50 Technology list, Adcore is a certified Google Premier Partner and Microsoft Partner.

Adcore serves hundreds of clients worldwide including: Digital Marketing Agencies, e-Commerce Businesses, Travel, Financial Technology and Gaming Companies and its strength as an agile and leading player in the industry has led to winning the largest online tender to date in Israel, a co-managed 5-year $125 million contract with the Israel Government Advertising Agency.

Established in 2006 and majority-owned by its founder and CEO, Mr. Omri Brill, the Corporation and its subsidiaries employs over thirty people in its headquarters in Tel Aviv, Israel and satellite offices in Melbourne, Australia, Toronto, Ontario and Winnipeg, Manitoba.

For more information about Adcore, please visit https://www.adcore.com/investor

FORWARD-LOOKING STATEMENTS

This press release contains certain forward-looking statements, including statements about the Corporation. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof.

Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Corporation cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Corporation assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

For further information please contact:

ADCORE INC.
Omri Brill, CEO
Telephone: 647-497-5337
Email: info@adcore.com
Website: www.adcore.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or the accuracy of this release.

SOURCE: Adcore Inc.

ReleaseID: 574361

VANCOUVER, BC / ACCESSWIRE / January 28, 2020 / Guyana Goldstrike Inc. (the "Company" or "Guyana Goldstrike") (TSXV:GYA, OTC PINK:GYNAF, FSE:1ZT) is pleased to announce the Company has signed a definitive gold forward purchase agreement (the "Agreement"), dated January 24, 2020, with an arms-length investor (the "Investor") for proceeds of up to US$9,000,000, for the Marudi Gold Project ("Marudi" or the "Property", or the "Project") located in Guyana, South America.

Under the terms of the Agreement, the Investor will make an initial payment of US$2,000,000 on or before April 14, 2020. Thereafter, a second payment of US$7,000,000 will be advanced within thirty days of a royalty interest in the Project in favour of the Investor having been registered.

The Agreement is non-dilutive to the Company's current share structure as no shares or warrants will be issued to the Investor. The proceeds will enable the Company to finalize its purchase of the Project and further explore and develop the resource potential of the Property.

In consideration for providing funding, the Company has agreed to deliver 30,000 ounces of gold, representing approximately 10% of the Project's current mineral resource estimate (please see "Mineral Resource Estimates" below). Deliveries will commence within 120 days of a declaration of commercial production from the Project, or within 36 months of the initial funding under the Agreement, whichever the earlier, with an annual delivery schedule of 3,000 ounces. The Company has also agreed to grant the Investor a right of first refusal to acquire a further 30,000 ounces of gold, on terms to be negotiated between the parties.

The delivery obligation of the Company will be secured by a 12.5% net smelter returns royalty in favour of the Investor, to be registered against the Project. The royalty will not be payable while the Company meets the deliver schedule and will expire once all delivery obligations under the Agreement have been satisfied.

Mineral Resource Estimates

The Mazoa Hill Zone contains the Company's current mineral resource estimate. Data analyzed suggests that the mineralized zone is open in several directions including at depth.

243,300 indicated gold ounces within 3,637,000 tonnes grading 2.1 g/t;
78,800 inferred gold ounces within 1,278,000 tonnes grading 1.9 g/t

For further information concerning the Mazoa Hill Zone Resource Estimate, readers are encouraged to review "Technical Report: Marudi Property Mazoa Hill Mineral Resource Estimate", a technical report prepared for the Company by Global Mineral Resource Services and is available at: GYA Mazoa Hill Zone 43-101, at the Company's website www.guyanagoldstrike.com and under the Company's profile on www.sedar.com.

Readers are cautioned that although the Project has a mineral resource estimate and a mining license a production decision has not been reached by the Company in respect of the Project, nor has a feasibility study been completed to assess the economic viability of commercial production at the Project. Also note, mineral resources that are not mineral reserves do not have demonstrated economic viability.

About Guyana Goldstrike Inc.

The Company is developing the Marudi Gold Project, which has a 17-year mining license and is located in Guyana, South America. Historic diamond drilling completed on the Project by prior operators have delineated two zones of gold mineralization: Mazoa Hill and Marudi North zones. A mineral resource estimate has been completed on the Mazoa Hill Zone. Data analyzed suggests the zone is open to mineralization in multiple directions and at depth.

Through the recent exploration program, the Company has discovered a third mineralized zone, called Toucan Ridge, which is situated approximately 1000 metres to the northeast of the Mazoa Hill Zone. In addition to the known gold zones and the new Toucan Ridge zone, the Company has over 45 sq. kms of underexplored land and believes the greater land position has excellent upside potential for the discovery of new mineralized zones through the development of previously and newly identified mineralized bedrock targets on the Project.

About Guyana

The Republic of Guyana is located in South America adjacent to Suriname. The country is English speaking and its legal system is based on British common law with a democratically elected government. It has an established mining act and a rich history of gold production. The Fraser Institute's 2016 Annual Survey of Mining listed Guyana as the third best mining jurisdiction with regards to investment attractiveness in the Latin America and Caribbean Basin sub-group. The Guiana Shield is the geographic gold-hosting region and is world-recognized as a premier gold region that is highly prospective, under-explored and has geological continuity with West Africa. Barrick has recently announced that the Giuana Shield will be their priority region for discovery opportunities and early stage exploration.* Exxon Recently announced the discovery of 6 billion barrels of offshore oil with production scheduled for first quarter of 2020. This discovery will designate Guyana as having the fastest growing GPD in 2020, estimated to be 86%.**

*https://www.reuters.com/article/us-barrick-gold-randgold-rsrcs-explorati/barrick-keen-on-guyana-shield-canada-for-exploration-executive-idUSKCN1NL276

**https://www.bloomberg.com/news/articles/2019-11-02/meet-the-economy-that-the-imf-sees-growing-86-in-2020

Qualified Person

Locke Goldsmith, M.Sc., P. Eng, P. Geo, Chief Geologist and Exploration Manager for the Company, is a Qualified Person in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Mr. Goldsmith has reviewed and approved the scientific and technical content of this news release.

On behalf of the Board of Directors of

GUYANA GOLDSTRIKE INC.

Peter Berdusco

President and Chief Executive Officer

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain certain "Forward-Looking Statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. When used in this news release, the words "anticipate", "believe", "estimate", "expect", "target, "plan", "forecast", "may", "schedule" and other similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to future prices of commodities, accuracy of mineral or resource exploration activity, reserves or resources, regulatory or government requirements or approvals, the reliability of third party information, continued access to mineral properties or infrastructure, fluctuations in the market for gold, changes in exploration costs and government regulation in Guyana, status of artisanal mining activities and associated rights, and other factors or information. Such statements represent the Company's current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affections such statements and information other than as required by applicable laws, rules and regulations.

SOURCE: Guyana Goldstrike Inc.

ReleaseID: 574352

Satellite Symposium will focus on the continued need for innovative drugs in ulcerative colitis, the novel mechanism of action of ABX464 as well as clinical data from the Phase 2a induction and maintenance studies
Event chaired by IBD key opinion leaders Prof. William Sandborn, M.D. (U.S.) and Prof. Xavier Hébuterne, M.D. (France)

PARIS, FRANCE / ACCESSWIRE / January 28, 2020 / Abivax (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announced that it will host a Satellite Symposium at the 15th Congress of ECCO, on February 13, 2020 from 12:00 to 01:00 p.m. CET. The ECCO Congress, taking place from February 12-15 in Vienna, Austria, is the world's leading congress focused on Inflammatory Bowel Diseases (IBD).

The Satellite Symposium will be chaired by Prof. William Sandborn, M.D., of the University of California San Diego School of Medicine, USA, and Prof. Xavier Hébuterne, M.D., of the CHU Nice, France, and is entitled "ABX464, a novel anti-inflammatory oral drug candidate based on a new mechanism of action to generate microRNA-124: From bench to bedside"

The focus of the symposium will be on the continued need for innovative drugs in ulcerative colitis as well as the novel mechanism of action and clinical data from the Phase 2a induction and maintenance studies with ABX464.
A complete program for the Abivax Satellite Symposium related to the 7th ClinCom Workshop can be viewed here.

Details of the Abivax Satellite Symposium at ECCO

Title:
ABX464, a novel anti-inflammatory oral drug candidate based on a new mechanism of action to generate microRNA-124: From bench to bedside

Time:
February 13, 2020 – 12:00-01:00 p.m. CET

Location:
Room Schubert 1-3 – Level 1, Reed Messe Wien, Austria

Speakers:

Prof. William Sandborn, M.D.
University of California San Diego School of Medicine, U.S.
Prof. Xavier Hébuterne, M.D.
CHU Nice, France
Didier Scherrer, Ph.D.
Abivax, France

About ABX464
ABX464 is a highly differentiated oral drug candidate, with a novel mechanism of action based on the upregulation of a single microRNA (miRNA-124) with potent anti-inflammatory properties. ABX464 was shown to exert its anti-inflammatory effects through binding to the cap binding complex (CBC), which sits at the 5' end of every RNA molecule in the cell. By binding to the CBC, ABX464 reinforces the biological functions of CBC in cellular RNA biogenesis. Specifically, ABX464 enhances the selective splicing of a single long non-coding RNA to generate the anti-inflammatory microRNA, miRNA-124, which downregulates pro-inflammatory cytokines and chemokines like TNF-α, IL-6 and MCP-1, thereby "putting a brake" on inflammation and suggesting broad potential as a novel anti-inflammatory therapeutic agent. A seven- to ten-fold increase in miRNA-124 levels was observed in colorectal biopsies of UC patients treated with ABX464. ABX464 does not impact the splicing of cellular genes. In addition to the ongoing Phase 2b trial in UC, ABX464 is also being investigated in a Phase 2a trial in rheumatoid arthritis and soon in a Phase 2b trial in Crohn's disease, where its effects could have significant potential.

About Abivax (www.abivax.com)
Abivax, a clinical stage company, is mobilizing the body's natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). More information on the company is available at www.abivax.com/en. Follow us on Twitter @ABIVAX.

Contacts:

Abivax
Communications
Regina Jehle
regina.jehle@abivax.com
+33 6 24 50 69 63
Investors
LifeSci Advisors
Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254
Public & Investor Relations Europe
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529 252 22

Public Relations France
Actifin
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 1 56 88 11 22
Public Relations France
Tilder
Marie-Virginie Klein
mv.klein@tilder.com
+33 1 44 14 99 96
Public Relations USA
Rooney Partners LLC
Marion Janic
mjanic@rooneyco.com
+1 212 223 4017

SOURCE: ABIVAX

ReleaseID: 574353

LOS ANGELES, CA / ACCESSWIRE / January 28, 2020 / Compare-autoinsurance.org has launched a new blog post that presents a few methods that can help seniors save car insurance money.

For more info and free car insurance quotes, please visit https://compare-autoinsurance.org/top-tips-for-the-elderly-to-get-better-car-insurance/

Insurance companies classify senior drivers as high-risk. The statistics show that the chances for an accident to happen are increasing for drivers that are 70 years old or older. The decline of hearing, eyesight, and reflexes combined with age-related diseases and medication are the main reasons why senior drivers are more likely to be involved in car crashes.

To save money on car insurance, senior drivers can follow the next tips:

Check the low-mileage discount. Most senior drivers are retired and they don't need to use their cars that much. Most insurance companies are offering a low-mileage discount to those drivers that manage to drive fewer miles than a certain threshold. Senior drivers should contact their insurers and check if they are eligible for this discount.
Join a defensive driving course. Graduating a defensive driving course will help senior drivers obtain a discount from their providers. These courses are cheap and they will help seniors recap their theoretical knowledge and to improve their driving skills. Besides that, seniors will learn how aging and medication can affect their driving skills.
Buy a car that is cheap to insure. Seniors should avoid buying the newest car models or expensive vehicles like limousines, muscle cars, or sports cars if they want to pay cheaper premiums. Slightly used sedans, family vans, or crossovers that are equipped with several safety features are among the cheapest vehicles to insure.
Maintain a clean driving record. Car insurance companies are offering discounts to drivers that maintain their driving records clean for a certain number of years. Senior drivers should contact their insurance carriers and check if they can qualify for this discount.
Shop around. The best method to check car insurance prices is by visiting brokerage websites. Senior drivers can use a brokerage website to obtain multiple quotes from different insurers. After comparing several quotes, senior drivers can decide if they will remain with their current provider or they will move to another one.

For additional info, money-saving tips and free car insurance quotes, visit https://compare-autoinsurance.org/

Compare-autoinsurance.org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc.

"Senior drivers can easily save money on car insurance, even though insurance companies classify them as high-risk. Several ingenious methods will help them pay affordable premiums", said Russell Rabichev, Marketing Director of Internet Marketing Company.

CONTACT:

Company Name: Internet Marketing Company
Person for contact Name: Gurgu C
Phone Number: (818) 359-3898
Email: cgurgu@internetmarketingcompany.biz
Website: https://compare-autoinsurance.org/

SOURCE: Internet Marketing Company

ReleaseID: 574310

NEW YORK, NY / ACCESSWIRE / January 28, 2020 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action filed on behalf of investors that purchased or acquired the securities of Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company") (NASDAQ:ADMS) between August 8, 2017, and September 30, 2019, inclusive (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934.

If you purchased Adamas securities, and/or would like to discuss your legal rights and options please visit Adamas Shareholder Class Action or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements, and failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, it is alleged that Defendants made materially false and misleading statements about: (1) managed care's acceptance of GOCOVRI; (2) the breadth of insurer coverage for GOCOVRI prescriptions; and (3) the impact of the Company's commercialization efforts. In addition, it is alleged that Defendants failed to disclose: (1) that health insurers were excluding GOCOVRI from their prescription formularies or requiring patients to use "step therapy" – i.e., making patients try immediate-release amantadine prior to covering GOCOVRI; (2) that the rapid increase in physicians prescribing GOCOVRI during the Class Period was not due to its efficacy; and (3) that, as a result of the foregoing, the Company's financial statements and Defendants' statements about Adamas's business, operations, and prospects, were materially false and misleading at all relevant times.

After the market closed on March 4, 2019, during Adamas's Q4 2018 conference call with investors, Adamas walked back its previous prescription growth estimates for GOCOVRI, warned of a continued slow-down in GOCOVRI prescriptions, and refused to make further predictions about GOCOVRI's ability to achieve a sizeable market share. On this news, Adamas's stock fell $3.99 per share, or 32.84%, to close at $8.16 per share on March 5, 2019.

On September 30, 2019, Bank of America/Merrill Lynch analyst Tazeen Ahmad lowered its rating for Adamas shares to "Underperform" noting "existing overhangs for ADMS: (1) Gocovri coverage: a number of national formularies exclude Gocovri. We expect reimbursement hurdles in MSWI space especially with generic Ampyra launch." On this news, Adamas shares fell a further 42.83% from $7.05 per share on September 26 to $4.03 by October 3, 2019.

If you purchased Adamas securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/adamaspharmaceuticalsinc-adms-shareholder-class-action-lawsuit-stock-fraud-229/apply/ or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com.

If you wish to serve as lead plaintiff, you must move the Court no later than February 10, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2020 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Matthew E. Guarnero
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
MGuarnero@bernlieb.com

SOURCE: Bernstein Liebhard LLP

ReleaseID: 573089

ALEXANDRIA, VA / ACCESSWIRE / January 28, 2020 / SOLEI SYSTEMS (OTC PINK:SOLI) a public holding company in the health and wellness field, is pleased to announce its application to the OTCQB Venture Market.

Today the company has initiated a strategy to upgrade its position in the public markets and increase its visibility to a wider range of investors through the process of uplisting to the OTCQB. The company has submitted the OTCQB application materials to OTC Markets Group.

President Josh Flood commented, "Uplisting to OTCQB is a natural milestone in Solei's growth journey. We are thrilled to further enhance our capabilities to deliver meaningful support services so individuals have better access to quality healthcare. Telemedicine is gaining momentum – and CareClix, Inc., our wholly owned subsidiary, is gaining traction and momentum in this sector."

The company already meets OTCQB Venture Market compliance requirements by filing audited annual financials prepared in accordance with U.S. GAAP which have been audited by a PCAOB auditor and maintains a Verified Company Profile at OTCMarkets.com.

For more information on Solei Systems, please visit the company's corporate website at http://www.soleihealth.com Investors wishing to subscribe to the company's Investor Alert system are asked to fill in the appropriate fields at the bottom of the Investor Relations page to receive notices of S.E.C. filings, press releases after they cross the newswire, periodic newsletters, and other information about Solei Systems' business that management believes will be of interest to holders of the company's stock.

About Solei

Solei Systems Inc is a fully reporting, fully audited public holding company in the health and wellness field with its primary focus on telemedicine. Currently, Solei Systems, Inc is comprised of two wholly owned subsidiaries: CareClix, Inc. and Clinical & Herbal Innovations, Inc.

Contact

Solei Systems, Inc
206 N. Washington St. Suite 100
Alexandria, VA 22314
T: (703) 832-4473
www.soleihealth.com

Cautionary Statement Regarding Forward-Looking Information

This press release may contain certain "forward-looking statements" relating to the business of Solei Systems Inc. All statements, other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

SOURCE: Solei Systems, Inc.

ReleaseID: 574343

DIDCOT, UK / ACCESSWIRE / January 28, 2020 / Altus Strategies Plc AIM:ALS & TSX-V:ALTS

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Altus Strategies Plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

X

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Euro Pacific Gold Fund LLC

City and country of registered office (if applicable)

Crownsville, Arundel County, Maryland, United States

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

27/01/2020

6. Date on which issuer notified (DD/MM/YYYY):

28/01/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

2.95%

2.95%

226,228,461

Position of previous notification (if

applicable)

3.79%

3.79%

176,132,686

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type of
shares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary 1p

GB00BYT26M80

6,680,000

n/a

2.95%

SUBTOTAL 8. A

6,680,000

2.95%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expiration
datex

Exercise/
Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration
datex

Exercise/
Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

Place of completion

Kansas City

Date of completion

28/01/2020

CONTACT:

Martin Keylock
07730985896
m.keylock@altus-strategies.com

SOURCE: Altus Strategies PLC

ReleaseID: 574336

NEW YORK, NY / ACCESSWIRE / January 28, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Fiat Chrysler Automobiles N.V. (NYSE:FCAU)
FCAU Lawsuit on behalf of: investors who purchased February 26, 2016 – November 20, 2019
Lead Plaintiff Deadline: January 31, 2020
Join the action: https://www.zlk.com/pslra-1/fiat-chrysler-automobiles-n-v-loss-form?wire=3&prid=5367

The lawsuit alleges: Fiat Chrysler Automobiles N.V. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company employed a bribery scheme to obtain favorable terms in its collective bargaining agreement with United Automobile, Aerospace and Agricultural Implement Workers of America; (2) high-ranking Fiat officials were aware of and authorized the scheme; and (3) as a result, Defendants' statements about Fiat's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

To learn more about the Fiat Chrysler Automobiles N.V. class action, contact jlevi@levikorsinsky.com.

Exelon Corporation (NYSE:EXC)
EXC Lawsuit on behalf of: investors who purchased February 9, 2019 – November 1, 2019
Lead Plaintiff Deadline: February 14, 2020
Join the action: https://www.zlk.com/pslra-1/exelon-corporation-loss-form?wire=3&prid=5367

The lawsuit alleges that, during the class period, Exelon Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) Exelon and/or its employees were engaged in unlawful lobbying activities; (ii) the foregoing increased the risk of a criminal investigation into Exelon; (iii) Exelon subsidiary Commonwealth Edison's revenues were in part the product of unlawful conduct and thus unsustainable; and (iv) that, as a result, the Company's public statements were materially false and misleading at all relevant times.

To learn more about the Exelon Corporation class action, contact jlevi@levikorsinsky.com.

Opera Limited (NASDAQ:OPRA)
OPRA Lawsuit on behalf of: investors who purchased (a) Opera American depositary shares pursuant and/or traceable to the Company's initial public offering commenced on or about July 27, 2018 and/or (b) Opera securities between July 27, 2018 and January 15, 2020,
Lead Plaintiff Deadline: March 24, 2020
Join the action: https://www.zlk.com/pslra-1/opera-limited-loss-form?wire=3&prid=5367

The lawsuit alleges: Opera Limited made materially false and/or misleading statements and/or failed to disclose that: (i) Opera's sustainable growth and market opportunity for its browser applications was significantly overstated; (ii) Defendants' funded, owned, or otherwise controlled loan services applications and/or businesses relied on predatory lending practices; (iii) all the foregoing, once revealed, were reasonably likely to have a material negative impact on Opera's financial prospects, especially with respect to its lending applications' continued availability on the Google Play Store; and (iv) as a result, the Offering Documents and Defendants' statements were materially false and/or misleading and failed to state information required to be stated therein.

To learn more about the Opera Limited class action, contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 574341

WHITE PLAINS, NY / ACCESSWIRE / January 28, 2020 / Rowley Law PLLC is investigating potential securities law violations by Delphi Technologies PLC (NYSE:DLPH) and its board of directors concerning the proposed acquisition of the company by BorgWarner, Inc. (NYSE:BWA). Stockholders will receive 0.4534 shares of BorgWarner common stock for each share of Delphi Technologies stock that they hold. The transaction is valued at approximately $3.3 billion and is expected to close the second half of 2020.

If you are a stockholder of Delphi Technologies PLC and are interested in obtaining additional information regarding this investigation, please visit us at: http://www.rowleylawpllc.com/investigation/dlph. You may also contact Shane Rowley, Esq. at Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at info@rowleylawpllc.com, or by telephone at 914-400-1920 or 844-400-4643 (toll-free).

Rowley Law PLLC represents shareholders nationwide in class actions and derivative lawsuits in complex corporate litigation. For more information about the firm and its attorneys, please visit http://www.rowleylawpllc.com.

Attorney Advertising. Prior results do not guarantee a similar outcome.

SOURCE: Rowley Law PLLC

ReleaseID: 574340